Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Gastro Retentive Drug Delivery System More
Adjuvant that induces a potent antigen-specific CD8 cytotoxic T-cell response with long lasting immunity More
This invention concerns a new approach to the treatment of rheumatoid arthritis (RA) by "tolerogenic vaccination" with small interfering RNA (siRNA) technology. More
This invention relates to a new siRNA-containing organ storage and reperfusion solution for use in transplantation. More
This technology is the first to show that subcutaneous administrations of chitosan and an appropriate antigen, with no other component, can be used for enhancing immune responses. More
A method of transfecting isolated autologous T-Lymphocytes with endogenous cytokines, for example IL-7 and IL-15, to sustain an adoptive T-lymphocyte response without systemic toxicity. More
Patented technology regarding a superior adjuvant with the active substance polysaccharide for oral/nasal vaccines against influenza and bird influenza, targeted to the aging population. More
AIDS, Novel antigen formed by specific molecular complex between the More
Treatment of Skin and Epithelial Tumors Using Intralesional Injection of Combined Antigens More
The present invention utilizes the characteristic chemical property of hydrazide groups on one reactant to react with aldehyde groups or cyanate esters on the other reactant with an improved conjugate yield of at least sixty percent. More
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Adoptive immunotherapy
- Amyloidosis
- Autoimmune disease (non-specific)
- Chronic fatigue syndrome
- Chronic granulomatous disease
- Chronic immunosuppression
- Gout
- Graft versus host disease
- HIV/AIDS
- Immune disorder (non-specific)
- Immune thrombocytopenic purpura
- Immunomodulation
- Immunostimulation
- Immunosuppression
- Lupus erythematosis
- Myalgic encephalomyelitis
- Myasthenia gravis
- Neoplastic disease
- Organ transplant rejection
- Rheumatoid arthritis
- Servere combined immunodeficency
- Sjogren's syndrome
- Systemic sclerosis
- Transplant rejection
- Xenotransplantation
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us